Competition Law360 provides breaking news and analysis on antitrust law. Coverage includes high-stakes antitrust litigation and government enforcement actions, as well as legislative and regulatory developments.

Sign up for a 7-day FREE trial today!

Latest News in Competition

• February 11, 2026

  Fed. Circ. Backs $85M Patent Antitrust Verdict Against Ingevity

  The Federal Circuit on Wednesday declined to disturb a Delaware jury's $85 million antitrust verdict against Ingevity over it tying patent licenses to purchases of its automobile carbon filtering technology, rejecting the company's arguments that it was entitled to a certain statutory patent misuse defense.

• February 11, 2026

  AGs Warn Cos. Plastic Initiatives May Break Competition Laws

  The attorneys general of 10 red states have warned 80 corporations that their purported involvement in organizations aiming to reduce plastic waste might run afoul of antitrust and consumer protection laws, following similar competition-focused actions targeting environmental and diversity groups at the state and federal levels.

• February 11, 2026

  CoStar Digs In On Quinn Emanuel DQ Bid In CREXi IP Suit

  CoStar doubled down on its efforts to disqualify Quinn Emanuel Urquhart & Sullivan LLP counsel from representing rival CREXi amid antitrust litigation in California federal court, reiterating that it's not bound by a conflict waiver signed by a company CoStar later acquired.

• February 11, 2026

  Luxottica Franchisee Gets Another Shot At Antitrust Claims

  An Ohio federal judge partially reversed course Wednesday after previously permanently tossing a Luxottica franchisee's antitrust claims, concluding that an attempt to amend them wouldn't be futile because it might be possible to show that allegedly suppressed insurance reimbursement rates were an ongoing violation that resets the statute of limitations.

• February 11, 2026

  Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now

  An Illinois federal judge on Wednesday tossed out Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug Tecfidera, but said the standing issues primarily dooming their complaint can likely be cured if they amend their pleading.

See more Competition news